Endometrial cancer is the most commonly diagnosed gynecological cancer. Credit: Darryl Leja, NHGRI.

Innovent Biologics has reported positive results from two clinical trials of IBI305 after meeting the pre-defined primary endpoints of both studies.

China-based Innovent’s IBI305 is a biosimilar of bevacizumab, which is a recombinant humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody developed for use as injection.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The CIBI305A301 and CIBI305A201 trials evaluated IBI305 in comparison with bevacizumab to treat advanced non-squamous non-small cell lung cancer (NSCLC), a type of epithelial lung cancer.

CIBI305A301 is a Phase III trial that evaluated the efficacy and safety of IBI305 and bevacizumab in patients with advanced non-squamous NSCLC.

“The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden.”

The randomised, double-blinded, parallel, positive-controlled trial enrolled 450 patients and aims to compare the clinical activity and safety of IBI305 and bevacizumab in combination with paclitaxel / carboplatin.

Its primary endpoint includes objective response rate (ORR).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The CIBI305A201 trial intends to investigate the pharmacokinetic profile, safety, tolerability, and immunogenicity of IBI305 in comparison with bevacizumab.

A total of 100 subjects were included in the randomised, double-blinded, parallel, positive-controlled single-dose trial.

Primary endpoint of the trial is to compare the pharmacokinetic (PK) profile of IBI305 and bevacizumab.

Innovent Biologics founder, CEO and chairman Michael Yu said: “The current morbidity and mortality of malignant tumours in China are high, and anti-tumour treatment is a significant economic burden for millions of families.

“Anti-angiogenic drugs are effective anti-tumour treatments, but as of yet there are no approved bevacizumab biosimilars in China.

“The clinical studies of IBI305, a potential biosimilar of bevacizumab, are encouraging.”

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now